Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...

Zenas BioPharma’s stock climbed 33% following a positive mid-phase trial readout for its lead candidate, obexelimab, in ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Health Canada grants authorization for Leqembi to treat early Alzheimer’s disease: Stockholm Tuesday, October 28, 2025, 10:00 Hrs [IST] BioArctic AB’s (publ) partner Eisai ann ...